The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Improving global access to novel immunotherapies for patients with R/R DLBCL
Despite recent advances in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including CAR-T and bispecific antibodies, there are still countries where access to such therapies is limited. Astrid Pavlovsky, MD, Pavlovsky Center for Hematology, Buenos Aires, Argentina, hopes that the community can collaborate to prevent this widening gap from growing and deliver novel therapies to all patients. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
